| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.4 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.024 | 0.4 |